First Heartland Consultants Inc. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 36.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 6,457 shares of the company’s stock after selling 3,676 shares during the quarter. First Heartland Consultants Inc.’s holdings in Johnson & Johnson were worth $892,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JNJ. Fundsmith Equity Fund L.P. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $552,762,000. Royal London Asset Management Ltd. acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $150,576,000. Flossbach Von Storch AG increased its stake in Johnson & Johnson by 53.3% in the 2nd quarter. Flossbach Von Storch AG now owns 3,553,636 shares of the company’s stock valued at $431,198,000 after buying an additional 1,235,186 shares during the last quarter. Public Employees Retirement Association of Colorado increased its stake in shares of Johnson & Johnson by 212.7% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 1,498,023 shares of the company’s stock worth $181,770,000 after purchasing an additional 1,019,002 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Johnson & Johnson by 58.2% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,602,167 shares of the company’s stock worth $221,371,000 after purchasing an additional 589,288 shares during the last quarter. Hedge funds and other institutional investors own 66.56% of the company’s stock.

NYSE JNJ opened at $138.02 on Friday. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $373.41 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 2.13 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. The firm had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.74 EPS. On average, research analysts forecast that Johnson & Johnson will post 8.57 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.61%. The ex-dividend date was Monday, February 25th. Johnson & Johnson’s dividend payout ratio is currently 44.01%.

Johnson & Johnson announced that its board has initiated a share buyback plan on Monday, December 17th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to buy up to 1.5% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

JNJ has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Wells Fargo & Co reiterated an “outperform” rating and issued a $152.00 price target (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Barclays reiterated an “equal weight” rating and issued a $135.00 price target (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Thursday, December 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $142.81.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2019/03/15/first-heartland-consultants-inc-sells-3676-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: How does new data get added to a blockchain?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.